Peginterferon for ET not controlled by hydroxyurea
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a new injectable medicine (Peginterferon α-2b) for people with essential thrombocythemia (ET) whose disease is not controlled by hydroxyurea (HU) or who cannot tolerate HU. It aims to help lower high platelet counts and reduce the risk of clots or bleeding.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older with high-risk essential thrombocythemia (ET).
- Hydroxyurea (HU) has not worked well for you or caused serious side effects.
- You have not used interferon therapy before, or if you did, it was at least 1 month ago.
- Your platelet count is currently above 450 and your blood counts (neutrophils, hemoglobin) are within safe limits.
- You do not have serious liver, kidney, eye, autoimmune, or heart problems, or active infections other than hepatitis B/C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called peginterferon for people with two blood disorders: essential thrombocythemia (too many platelets) and polycythemia vera (too many red blood cells). The goal is to see if peginterferon can help control these conditions and is safe.
This study tests a new drug called INCA033989 for people with a high-risk form of essential thrombocythemia (a blood disorder causing too many platelets) who have a specific genetic change called mutCALR. The trial compares this new drug to the best currently available treatments.
This study tests an injection called BEBT-507 for people with polycythemia vera (a blood condition that makes too many red blood cells). It's for those who haven't responded well to or can't tolerate standard treatments like hydroxyurea or interferon. The goal is to see if this new drug can help control the disease.
This Phase 2 trial tests a combination of pegylated interferon and ruxolitinib in adults with polycythemia vera who can’t tolerate hydroxyurea or don’t respond well to it. If you qualify, it may help control blood counts and disease symptoms when standard treatment hasn’t worked.
This trial tests a sequence of pegylated interferon (PEG-IFN) shots for people with chronic hepatitis B who have already had a significant drop in their virus levels after taking a newer type of RNA-targeting medicine. The goal is to see if this approach can help clear the virus even further.
This trial tests a combination of two drugs—gecacitinib (a JAK inhibitor) and pegylated interferon—to see if they work better together for people with polycythemia vera (PV), a blood cancer that causes too many red blood cells. The study is for patients who have not tried these specific treatments before and who have symptoms like high blood counts, weight loss, night sweats, or an enlarged spleen.
Hear when a new Essential Thrombocythemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.